Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 48, Issue 2 (Feb 2010)

Issues

Determination of globotriaosylceramide in plasma and urine by mass spectrometry

Ralf Krüger
  • Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany
/ Kai Bruns
  • Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany
  • Present address: Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.
/ Silke Grünhage
  • Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany
/ Heidi Rossmann
  • Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany
/ Jörg Reinke
  • Department of Pediatrics/Villa Metabolica, Medical Center of the Johannes Gutenberg University, Mainz, Germany
/ Michael Beck
  • Department of Pediatrics/Villa Metabolica, Medical Center of the Johannes Gutenberg University, Mainz, Germany
/ Karl J. Lackner
  • Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany
Published Online: 2009-12-04 | DOI: https://doi.org/10.1515/CCLM.2010.048

Abstract

Background: Fabry disease is an X-chromosomally inherited lysosomal storage disorder leading to accumulation of glycosphingolipids, mainly globotriaosylceramide (ceramide-trihexoside, Gb3). Concentrations of Gb3 in plasma and urine have been used to diagnose Fabry disease and to monitor enzyme replacement therapy with recombinant α-galactosidase.

Methods: Gb3 was purified from plasma or urine by combined liquid extraction/protein precipitation and solid-phase extraction, and was detected by flow-injection analysis electrospray mass spectrometry (MS) using multi-reaction-monitoring. Calibration was performed via standard addition using C17-Gb3 as internal standard. The most abundant isoforms were monitored for calculation of total Gb3.

Results: A MS-based assay for quantification of Gb3 in plasma and urine was established and validated. Intra- and inter-assay coefficient of variation (CV) of the method were ≤12%. However, at low concentrations the CV was 16%. The linear range covers roughly two orders of magnitude, down to 0.54 mg/L in plasma and 0.07 mg/L in urine. Careful adjustment of tuning parameters was necessary to obtain identical isoform intensities and quantitative results on different mass spectrometers. Gb3 concentrations in healthy controls were <4 mg/L in EDTA-plasma and <10 μg/mmol creatinine in urine. Significantly increased Gb3 concentrations were found in plasma and urine from male and female patients with Fabry disease.

Conclusions: An improved MS protocol for Gb3 quantification has been developed, validated, and shown to be suitable for diagnosis and monitoring of Fabry patients.

Clin Chem Lab Med 2010;48:189–98.

Keywords: Fabry disease; Gb3 (globotriaosylceramide); glycosphingolipid; liquid chromatography-tandem mass spectrometry; lysosomal storage disorder

About the article

Corresponding author: Dr. Ralf Krüger, Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany


Received: 2009-07-10

Accepted: 2009-10-07

Published Online: 2009-12-04

Published in Print: 2010-02-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2010.048.

Export Citation

©2010 by Walter de Gruyter Berlin New York. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Sandra Merscher and Alessia Fornoni
Frontiers in Endocrinology, 2014, Volume 5
[2]
Hany Farwanah and Thomas Kolter
Metabolites, 2012, Volume 2, Number 4, Page 134
[3]
J. Lukas, J. Torras, I. Navarro, A.-K. Giese, T. Bottcher, H. Mascher, K. J. Lackner, G. Fauler, E. Paschke, J. M. Cruzado, A. Dudesek, M. Wittstock, W. Meyer, and A. Rolfs
Clinical Kidney Journal, 2012, Volume 5, Number 5, Page 395
[4]
D. Ryan, K. Robards, P.D. Prenzler, and Megan Kendall
Analytica Chimica Acta, 2011, Volume 684, Number 1-2, Page 17
[5]
C. Tanislav, M. Kaps, A. Rolfs, T. Böttcher, K. Lackner, E. Paschke, H. Mascher, M. Laue, and F. Blaes
European Journal of Neurology, 2011, Volume 18, Number 4, Page 631
[6]
Journal of Mass Spectrometry, 2010, Volume 45, Number 7, Page 829

Comments (0)

Please log in or register to comment.
Log in